<DOC>
	<DOC>NCT02216513</DOC>
	<brief_summary>The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.</brief_summary>
	<brief_title>Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Subarachnoid Hemorrhage</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>diagnosis of spontaneous SAH impaired cerebral autoregulation on day 24 post SAH traumatic SAH other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations pregnancy severe renal disease or anuria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>subarachnoid hemorrhage</keyword>
	<keyword>SAH</keyword>
	<keyword>DFO</keyword>
	<keyword>cerebral autoregulation</keyword>
	<keyword>delayed cerebral ischemia</keyword>
</DOC>